Lytica Therapeutics

Antimicrobial peptide Design

Lytica Therapeutics is focused on developing novel peptide therapeutics. Traditional antibody drug conjugates (ADCs) contain the targeted antibodies and attached cytotoxic payloads. Lytica is redefining ADC design by building unique conjugates that give antibodies new therapeutic properties. To discover new functions, Lytica is using their stapled peptide platform that uses peptide-based conjugates that are faster to develop as well as providing modularity and stabilizing properties. With this approach, Lytica can unlock previously undruggable targets, opening up a new landscape of possible treatment options.